New pill shows early promise against tough cancers

NCT ID NCT06245122

Recruiting now Disease control Sponsor: Chipscreen Biosciences, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Researchers will also look for early signs that the drug is fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS23546 (an oral drug that may help the immune system fight cancer)
What this could lead to: If this drug is safe and shows promise, it could lead to a new treatment option for people with advanced cancers that have stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 156 participants, so the drug may not work or could have serious side effects. Success in this small study does not guarantee it will help future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma lymphoma neoplasm soft tissue sarcoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TUMORS

Contacts and locations

Locations

Sun Yat-sen University Cancer Cancer
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.